SUMO-C1 corresponded to a tumor immunoinflammatory phenotype with better overall survival, significant activation of immune pathways such as the IL2, inflammatory, complement, and allograft rejection pathway, and increased infiltration levels of anti-tumor immune cells. Here, IL2 is linked to neoplasm.